Seeking Alpha

Biogen Idec (BIIB) has agreed to acquire full ownership of multiple-sclerosis drug Tysabri from...

Biogen Idec (BIIB) has agreed to acquire full ownership of multiple-sclerosis drug Tysabri from Elan (ELN) for $3.25B plus future royalty payments. Biogen has co-marketed the injectable treatment, which generated revenue of $1.6B last year, with Elan for twelve years, with both firms splitting the profit until now. The deal comes as Biogen awaits approval for its BG-12 pill to treat MS. (PR)
Comments (1)
  • Michael Bryant
    , contributor
    Comments (5775) | Send Message
     
    (ELN) has a market cap of $6.2 billion, so deal about half ELN's market cap. Not bad.
    6 Feb 2013, 08:27 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs